Eli Lilly reported 39% revenue growth and 7% non-GAAP earnings-per-share growth, including acquisition costs. Management raised 2026 revenue guidance to $91.5 billion at the midpoint (from $86 billion) and trimmed non-GAAP EPS guidance to $35.50 at the midpoint from $36, accounting for acquisitions.
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth, given its approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
The risks to success for Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition, particularly from Eisai/Biogen (Leqembi) and Roche (pipeline drug trontinemab).
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 43.62 | 8.68 | 45.59 |
Price/Book Value | 30.40 | 5.12 | 8.61 |
Price/Sales | 14.22 | 3.38 | 5.37 |
Price/Cash Flow | 33.96 | 8.10 | 16.38 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.64 | 0.64 | 0.71 |
Current Ratio | 1.39 | 0.87 | 1.32 |
Interest Coverage | 33.96 | — | 4.28 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 28.08% | 21.31% | 6.27% |
Return on Equity (Normalized) | 114.41% | 59.99% | 16.68% |
Return on Invested Capital (Normalized) | 46.92% | 34.79% | 9.74% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Johnson & Johnson
JNJ
| LOCK|@F%m@ff | LOCK|N&p | $662B | |||
| AbbVie Inc
ABBV
| LOCK|rq?bl< | LOCK|wF< | $514B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|H^Gqyp#h | LOCK|sW | $388B | |||
| Merck & Co Inc
MRK
| LOCK|^cT<?f | LOCK|?H | $361B | |||
| Novartis AG ADR
NVS
| LOCK|$k^#k<& | LOCK|hb! | $302B | |||
| AstraZeneca PLC
AZN
| LOCK|xYJB$b!? | LOCK|F%$ | $270B | |||
| Amgen Inc
AMGN
| LOCK|p$f!K>#F | LOCK|X?L | $249B | |||
| Gilead Sciences Inc
GILD
| LOCK|MVC<Mr | LOCK|Fm | $205B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!Y^<@D | LOCK|%@% | $171B |
United States